Page 55 - Read Online

Page 18 of 19 Hewitt et al. Hepatoma Res 2021;7:75 https://dx.doi.org/10.20517/2394-5079.2021.83

postoperative complications. World J Surg 2007;31:1256-63. DOI PubMed
101. Zhang XF, Squires MH 3rd, Bagante F, et al. The impact of intraoperative re-resection of a positive bile duct margin on clinical
outcomes for hilar cholangiocarcinoma. Ann Surg Oncol 2018;25:1140-9. DOI PubMed
102. Neuhaus P, Jonas S, Bechstein WO, et al. Extended resections for hilar cholangiocarcinoma. Ann Surg 1999;230:808-18; discussion
819. DOI PubMed PMC
103. Edge SB, Compton CC. The American Joint Committee on cancer: the 7th edition of the AJCC cancer staging manual and the future
of TNM. Ann Surg Oncol 2010;17:1471-4. DOI PubMed
104. Lim JH, Choi GH, Choi SH, Kim KS, Choi JS, Lee WJ. Liver resection for Bismuth type I and Type II hilar cholangiocarcinoma.
World J Surg 2013;37:829-37. DOI PubMed
105. de Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of
prognostic factors and lymph node assessment. J Clin Oncol 2011;29:3140-5. DOI PubMed
106. Zhang XF, Chen Q, Kimbrough CW, et al. Lymphadenectomy for intrahepatic cholangiocarcinoma: has nodal evaluation been
increasingly adopted by surgeons over time? J Gastrointest Surg 2018;22:668-75. DOI PubMed
107. Ercolani G, Grazi GL, Ravaioli M, et al. The role of lymphadenectomy for liver tumors: further considerations on the appropriateness
of treatment strategy. Ann Surg 2004;239:202-9. DOI PubMed PMC
108. Kitagawa Y, Nagino M, Kamiya J, et al. Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent
regional and paraaortic node dissection. Ann Surg 2001;233:385-92. DOI PubMed PMC
109. Kim SH, Han DH, Choi GH, Choi JS, Kim KS. Extent of lymph node dissection for accurate staging in intrahepatic
cholangiocarcinoma. J Gastrointest Surg 2021. DOI PubMed
110. Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a
population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin 2017;67:93-9. DOI PubMed
111. Marsh Rde W, Alonzo M, Bajaj S, et al. Comprehensive review of the diagnosis and treatment of biliary tract cancer 2012. Part I:
diagnosis-clinical staging and pathology. J Surg Oncol 2012;106:332-8. DOI PubMed
112. DeOliveira ML, Kambakamba P, Clavien PA. Advances in liver surgery for cholangiocarcinoma. Curr Opin Gastroenterol
2013;29:293-8. DOI PubMed
113. Razumilava N, Gores GJ. Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol 2013;11:13-
21.e1; quiz e3-4. DOI PubMed PMC
114. Loehrer AP, House MG, Nakeeb A, Kilbane EM, Pitt HA. Cholangiocarcinoma: are North American surgical outcomes optimal? J
Am Coll Surg 2013;216:192-200. DOI PubMed
115. Ebata T, Yokoyama Y, Igami T, et al. Hepatopancreatoduodenectomy for cholangiocarcinoma: a single-center review of 85
consecutive patients. Ann Surg 2012;256:297-305. DOI PubMed
116. Hemming AW, Magliocca JF, Fujita S, et al. Combined resection of the liver and pancreas for malignancy. J Am Coll Surg
2010;210:808-14, 814-6. DOI PubMed
117. Sarmiento JM, Nagorney DM, Sarr MG, Farnell MB. Periampullary cancers: are there differences? Surg Clin North Am 2001;81:543-
55. DOI
118. Askew J, Connor S. Review of the investigation and surgical management of resectable ampullary adenocarcinoma. HPB (Oxford)
2013;15:829-38. DOI PubMed PMC
119. Cloyd JM, Ejaz A, Pawlik TM. The landmark series: intrahepatic cholangiocarcinoma. Ann Surg Oncol 2020;27:2859-65. DOI
PubMed
120. Gamboa AC, Maithel SK. The landmark series: gallbladder cancer. Ann Surg Oncol 2020;27:2846-58. DOI PubMed
121. Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin
Oncol 2019;37:1015-27. DOI PubMed
122. Cloyd JM, Pawlik TM. Adjuvant therapy for biliary tract cancers: new evidence to resolve old questions. J Oncol Pract 2018;14:723-
4. DOI PubMed
123. Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-
analysis. J Clin Oncol 2012;30:1934-40. DOI PubMed
124. Ghidini M, Tomasello G, Botticelli A, et al. Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-
analysis. HPB (Oxford) 2017;19:741-8. DOI PubMed
125. Takada T, Amano H, Yasuda H, et al; Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract.
Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? Cancer 2002;95:1685-95. DOI PubMed
126. Valle J, Wasan H, Palmer DH, et al; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract
cancer. N Engl J Med 2010;362:1273-81. DOI PubMed
127. André T, Reyes-Vidal JM, Fartoux L, et al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J
Cancer 2008;99:862-7. DOI PubMed PMC
128. Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract
cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol 2019;37:658-67. DOI PubMed
129. Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a
randomised, controlled, multicentre, phase 3 study. Lancet Oncol 2019;20:663-73. DOI PubMed
130. Ebata T, Hirano S, Konishi M, et al; Bile Duct Cancer Adjuvant Trial (BCAT) Study Group. Randomized clinical trial of adjuvant
gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg 2018;105:192-202. DOI PubMed
131. Itano O, Takemura Y, Kishida N, et al. A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected